clinical trial · NCT04895696
A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
Bristol-Myers Squibb·phase2·active not recruiting·n = 268
Systemic Lupus ErythematosusAfimetoranPlacebo
brief summary
The purpose of this study is to evaluate the effectiveness, safety and tolerability of Afimetoran in participants with active Systemic Lupus Erythematosus (SLE). The extension period will provide additional long-term safety and efficacy data and enable those participants initially randomized to placebo to receive treatment with Afimetoran.
started
Oct 11, 2021
primary completion
Mar 29, 2026
completion
Apr 22, 2029
last updated
Jun 10, 2025
official title
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Afimetoran in Participants With Active Systemic Lupus Erythematosus
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol